Autoantibodies to oxidized LDL and cardiovascular risk: The Framingham Offspring Study

Atherosclerosis

Volumn 189, Issue 2, 2006, Pages 364-368

  Wilson, Peter W F ^a,b   Ben Yehuda, Ori ^c   McNamara, Judy ^d   Massaro, Joseph ^b   Witztum, Joseph ^c   Reaven, Peter D ^e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TUFTS UNIVERSITY   (United States)

^e CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Autoantibodies; Cardiovascular disease; Epidemiology; Oxidation; Risk factors

Indexed keywords

AUTOANTIBODY; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G ANTIBODY; LIPID; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; ISCHEMIC HEART DISEASE; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGENY; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING;

ADULT; ADULT CHILDREN; AGE FACTORS; AGED; ANTIBODIES, ANTI-IDIOTYPIC; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 33750991054     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.12.013     Document Type: Article

References (36)

1. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
2. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001) 1108-1113
3. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol: modifications of low-density lipoproteins that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
4. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 344 (1994) 793-795
5. Austin M.A., King M.C., Vranizan K.M., and Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82 (1990) 495-506
6. Liao L., Starzyk R.M., and Granger D.N. Molecular determinants of oxidized low-density lipoprotein-induced leukocyte adhesion and microvascular dysfunction. Arterioscler Thromb Vasc Biol 17 (1997) 437-444
7. Calara F., Dimayuga P., Niemann A., et al. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 18 (1998) 884-893
8. Ananyeva N.M., Tjurmin A.V., Berliner J.A., et al. Oxidized LDL mediates the release of fibroblast growth factor-1. Arterioscler Thromb Vasc Biol 17 (1997) 445-453
9. Wolin M.S. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol 20 (2000) 1430-1442
10. Lougheed M., Moore E.D., Scriven D.R., and Steinbrecher U.P. Uptake of oxidized LDL by macrophages differs from that of acetyl LDL and leads to expansion of an acidic endolysosomal compartment. Arterioscler Thromb Vasc Biol 19 (1999) 1881-1890
11. Zhou X., Caligiuri G., Hamsten A., Lefvert A.K., and Hansson G.K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 108-114
12. Landmesser U., and Harrison D.G. Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 104 (2001) 2638-2640
13. Heitzer T., Schlinzig T., Krohn K., Meinertz T., and Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001) 2673-2678
14. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955-1960
15. Salonen J.T., Yla-Herttuala S., Yamamoto R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 (1992) 883-887
16. Bergmark C., Wu R., de Faire U., Lefvert A.K., and Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 15 (1995) 441-445
17. Hulthe J., Bokemark L., and Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21 (2001) 101-107
18. Maggi E., Chiesa R., Melissano G., et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14 (1994) 1892-1899
19. Maor I., Hayek T., Coleman R., and Aviram M. Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 17 (1997) 2995-3005
20. Hulthe J., Wikstrand J., Lidell A., et al. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 18 (1998) 1203-1211
21. Uusitupa M.I., Niskanen L., Luoma J., et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16 (1996) 1236-1242
22. Stout R.W. Insulin and atheroma: 20-Yr perspective. Diabetes Care 13 (1990) 631-654
23. van de Vijver L.P., Kardinaal A.F., van Duyvenvoorde W., et al. LDL oxidation and extent of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 18 (1998) 193-199
24. D'Agostino Sr. R.B., Grundy S., Sullivan L.M., and Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286 (2001) 180-187
25. Meigs J.B., Mittleman M.A., Nathan D.M., et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283 (2000) 221-228
26. Gebara O.C.E., Mittleman M.A., Sutherland P., et al. Association between increased estrogen status and incrased fibrinolytic potential in the Framingham Offspring Study. Circulation 91 (1995) 1952-1958
27. Poli K.A., Tofler G.H., Larson M.G., et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population [in process citation]. Circulation 101 (2000) 264-269
28. Muller J.E., et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 69 (1984) 740-747
29. Fukumoto M., Shoji T., Emoto M., et al. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 20 (2000) 703-707
30. Palinski W., Tangirala R.K., Miller E., Young S.G., and Witztum J.L. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 15 (1995) 1569-1576
31. Ameli S., Hultgardh-Nilsson A., Regnstrom J., et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16 (1996) 1074-1079
32. Brennan M.L., Penn M.S., van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
33. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481-2485
34. Manolio T. Novel risk markers and clinical practice. N Engl J Med 349 (2003) 1587-1589
35. Lopes-Virella M.F., and Virella G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front Biosci 8 (2003) s750-s768
36. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005) 46-57